Gossamer Bio (GOSS): Analyst Targets Point to +780% Upside Potential

Key Takeaways

• The central target of $86 is the arithmetic mean of five clearly attributed, post-split analyst price targets, rounded from an underlying mean of about $86.40.
• With the stock near $9.77, reaching $86 would require an increase of roughly 780% — an exceptionally large move typical of a binary, pre-revenue biotech.
• The analyst target range is extraordinarily wide, from $22 (Barclays) to $160 (Chardan Capital), reflecting sharply divided views on seralutinib's path to U.S. Food and Drug Administration (FDA) approval.
• The strongest support is a submitted New Drug Application (NDA) for seralutinib in PAH, backed by positive Phase 2 data and a large, poorly served patient market.
• The biggest risk is single-asset concentration: the Phase 3 PROSERA study missed its primary endpoint on statistical significance, leaving approval far from assured.
• Investors can find additional detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• For AI-driven market analysis across many tickers, explore Trending AI Robots.

Understanding the Analyst Consensus on GOSS

The central target of $86 represents a calculated mean rather than an official published consensus. The five clearly attributed, post-reverse-split targets I reviewed are: Chardan Capital at $160 (Buy, October 2026), H.C. Wainwright at $90 (Buy, September 2026, adjusted for the split), Wedbush at $80 (Hold, August 2026), Leerink Partners at $80 (Outperform, July 2026), and Barclays at $22 (Sell/Underweight, July 2026). These average about $86.40, which rounds to the central target of $86, with a low-to-high range of $22 to $160.

Broader aggregators show a larger analyst pool and a mean near $95, but several entries appear pre-split or stale, so the five post-split figures stand as the cleanest basis. The wide dispersion stems from the company's value hinging almost entirely on one binary event — whether the FDA approves seralutinib. Bullish firms, led by Chardan's framing of highly asymmetric risk/reward, see a top small-cap opportunity, while Barclays' target reflects materially lower conviction in the regulatory outcome. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

At roughly $9.77 per share, GOSS carries a market capitalization near $60 million — micro-cap territory. Reaching $86 would require the stock to appreciate by about 780%, a very large move that, in practice, would most plausibly be driven by positive FDA news rather than gradual appreciation.

The company submitted its first NDA for seralutinib in PAH in September 2026, drawing on the Phase 3 PROSERA study, the Phase 2 TORREY study, and supportive subgroup analyses. The challenge is that PROSERA's topline result missed statistical significance on its primary endpoint, leaving analysts to debate whether the FDA will accept the totality of the data package. Any path toward $86 therefore runs directly through the regulatory process.

Factors That Could Support a Move Toward the Target

• Regulatory acceptance and approval: FDA agreement to file, and ultimately approve, the NDA would transform the company's risk profile.
• Clinical evidence: TORREY demonstrated positive Phase 2 results, and management argues the FDA is reviewing the full data package, not just the PROSERA miss.
• Market opportunity: PAH is a serious, underserved indication, and seralutinib's novel mechanism — an inhaled PDGFR, CSF1R, and c-KIT inhibitor — targets disease remodeling rather than only vasodilation.
• Partnerships: A global collaboration with the Chiesi Group, alongside the reacquisition of worldwide seralutinib rights, broadens the commercial reach if approval comes.
• Recent upgrades: Leerink's July upgrade to Outperform signaled renewed comfort with the regulatory setup.

Factors That Could Prevent the Target From Being Reached

• Regulatory failure: A refusal-to-file letter or an FDA rejection would likely undermine the bull case and could pressure the stock sharply.
• Single-asset concentration: With essentially one late-stage drug, Gossamer Bio carries concentrated clinical and execution risk.
• PROSERA's statistical miss: Analysts including Piper Sandler have flagged the degree of treatment effect and statistical significance as a genuine review issue.
• Cash runway: Reported funding extends only to roughly the first half of 2027, creating potential dilution or financing risk if approval is delayed.
• Valuation and sentiment: As a pre-revenue biotech, the shares are highly sensitive to headline risk and sector-wide risk appetite.

Technical Levels and Market Structure

Following the 1-for-80 reverse split, historical technical levels are distorted and of limited predictive value. The stock trades far below even the lowest bull-case target, with $10 serving as a near-term psychological reference point. In this context, price action is more likely to be driven by regulatory headlines and analyst revisions than by durable chart levels, so conventional support and resistance zones should be interpreted cautiously.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though specific timeframes vary by firm and were not uniformly disclosed. Key upcoming items include the FDA's decision on whether to accept the NDA for filing, subsequent review milestones, any additional seralutinib data disclosures, financing activity, and analyst target revisions. Investors should also watch collaboration developments with Chiesi and any updates to the cash runway.

Using AI Daily Buy/Sell Signals in Practice

In my own work, I rely on Tickeron’s AI Daily Buy/Sell Signals to help track event-driven names like this one. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a volatile stock such as GOSS, these signals can complement manual research by highlighting trend changes more efficiently.

Final Assessment

The question of whether GOSS can reach $86 is, in substance, a question about seralutinib's approval odds. The calculated central target of $86 — a mean of five post-split analyst targets spanning $22 to $160 — implies roughly 780% upside from the current price near $9.77, an enormous move that reflects the binary nature of the situation. Bullish analysts point to the submitted NDA, positive Phase 2 evidence, and a large market; cautious analysts emphasize the PROSERA statistical miss, single-asset risk, and a limited cash runway. There is no guarantee the stock reaches the target, and investors should focus next on the FDA's filing decision and any clinical or financing updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume